Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations (Unaudited)

v3.22.2.2
Condensed Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses:        
Research and development $ 955 $ 787 $ 3,523 $ 2,127
Selling, general and administrative 2,160 4,865 8,634 14,184
Total operating expenses 3,115 5,652 12,157 16,311
Loss from operations (3,115) (5,652) (12,157) (16,311)
Other income (expense):        
Other income (expense) (49) (42)
Interest expense (1) (2) (6) (535)
Loss on exchange of notes payable for common stock and warrants (6)
Gain (loss) on extinguishment of debt (13,805)
Change in fair value of warrant liability (1,024)
Change in fair value of derivative liability (51)
Total other income (expense) (1) (51) (6) (15,463)
Net loss (3,116) (5,703) (12,163) (31,774)
Cumulative dividends on Series D preferred stock (23)   (23)  
Net loss attributable to common stockholders $ (3,139) $ (5,703) $ (12,186) $ (31,774)
Net loss per share attributable to common stockholders (in Dollars per share) $ (0.18) $ (0.39) $ (0.73) $ (2.32)
Weighted average shares outstanding, basic and diluted: (in Shares) 17,644,188 14,510,818 16,646,616 13,669,445